Nuclear factor κB inducing factor
View Patent ↗The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFκB induction in a patient, methods and compositions for lowering NFκB induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.
1. An isolated nucleic acid encoding NFIF-14b polypeptide comprising an amino acid sequence as shown in FIG. 1 (SEQ ID NO:1).
2. The nucleic acid of claim 1 wherein said nucleic acid is a cDNA.
3. An isolated expression vector comprising the nucleic acid of claim 2 operably linked to a control sequence.
4. The expression vector of claim 3 wherein said expression vector is selected from the group consisting of retroviral vectors, adenoviral vectors, adeno-associated viral vectors, herpes viral vectors, and naked DNA vectors.
5. A cultured cell comprising the vector of claim 3 .
6. A cultured cell transfected with the vector of claim 3 , or a progeny of said cell, wherein the cell expresses said NFIF-14b polypeptide comprising an amino acid sequence of FIG. 1 (SEQ ID NO:1).
7. A pharmaceutical composition, comprising a therapeutically effective amount of an isolated expressible nucleic acid sequence encoding an NFIF-14b polypeptide comprising the amino acid sequence shown in FIG. 1 (SEQ ID NO: 1), and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition, comprising a therapeutically effective amount of a recombinant vector comprising an expressible nucleic acid sequence encoding an NFIF-14b polypeptide comprising the amino acid sequence shown in FIG. 1 (SEQ ID NO: 1), and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition, comprising a therapeutically effective amount of a defective recombinant viral vector comprising an expressible nucleic acid sequence encoding an NFIF-14b polypeptide comprising the amino acid sequence shown in FIG. 1 (SEQ ID NO: 1), and a pharmaceutically acceptable carrier.